New syndicated reports: Cancer monitoring US landscape
As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants.
Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 3 are available for immediate purchase, with Wave 4 launching soon.
Are you seeking answers to key questions such as: Are ctDNA monitoring tests being used in clinical practice? Which tests are Oncologists currently using, and why? What unmet needs and expectations do Oncologists have for future tests?
The methodology consists of 20-minute quantitative online interviews with 150 Medical and Hemato-Oncologists in the US. The research explores current and anticipated usage of ctDNA monitoring across different cancer stages, revealing the preferences and needs of Oncologists. Further insights are revealed around behaviours and perceptions surrounding this new trending indication.
Request the wave 3 sample report via the form below:
Privacy Note: At Purdie Pascoe, we occasionally share the latest MedTech news and insights that we believe may be of interest to you. We will only contact you about topics relevant to your preferences. Your privacy is important to us — you can unsubscribe from our communications at any time. For more information, please see our Privacy Policy.
Why invest in these reports?
.Gain a high-level overview of the ctDNA monitoring landscape to guide your tailored research initiatives
Inform your testing strategy, particularly around MRD, and understand how ctDNA adoption may shape your commercial plans
Explore ctDNA monitoring adoption by practice type and tumour type
Track market evolution over the next two years